Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Visa Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Visa Inc trades at $385.45 (market cap $704.20B). The key difference: Visa Inc is far larger — about 56× Halozyme Therapeutics Inc. Common Stock's market cap, and Visa Inc pays a 0.71% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Visa Inc for 115 Days on average.
| HALO | V | |
|---|---|---|
Market Cap | $12.58B | $704.20B |
Volume | 2,179,278 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $115.22 | $384.14 |
52-Week Low | $61.63 | $295.52 |
Typical Hold Time | 1 Days | 115 Days |
Enterprise Value | $14.49B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $385.45, up 3.59% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 50.78% net income margin and consistent earnings beats. Recent news highlights Visa's AI-driven initiatives like Intelligent Commerce Connect and partnerships to advance stablecoin adoption, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $422.24, implying 9.5% upside. Risks include competitive fintech threats and regulatory pressures. The company's high profitability and strategic focus on AI and digital payments support long-term investment appeal, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
